Cargando…

Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy

Kidney transplant recipients are at particular risk for developing tumors, many of which are now routinely treated with immune checkpoint inhibitors (ICIs); however, ICI therapy can precipitate transplant rejection. Here, we use TCR sequencing to identify and track alloreactive T cells in a patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunlap, Garrett S., DiToro, Daniel, Henderson, Joel, Shah, Sujal I., Manos, Mike, Severgnini, Mariano, Weins, Astrid, Guleria, Indira, Ott, Patrick A., Murakami, Naoka, Rao, Deepak A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027853/
https://www.ncbi.nlm.nih.gov/pubmed/36941274
http://dx.doi.org/10.1038/s41467-023-37230-4
Descripción
Sumario:Kidney transplant recipients are at particular risk for developing tumors, many of which are now routinely treated with immune checkpoint inhibitors (ICIs); however, ICI therapy can precipitate transplant rejection. Here, we use TCR sequencing to identify and track alloreactive T cells in a patient with melanoma who experienced kidney transplant rejection following PD-1 inhibition. The treatment was associated with a sharp increase in circulating alloreactive CD8(+) T cell clones, which display a unique transcriptomic signature and were also detected in the rejected kidney but not at tumor sites. Longitudinal and cross-tissue TCR analyses indicate unintended expansion of alloreactive CD8(+) T cells induced by ICI therapy for cancer, coinciding with ICI-associated organ rejection.